| Pembrolizumab |
EU/1/15/1024/001 |
Keytruda, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
Schering-Plough Labo NV, Industriepark 30 Heist-op-den-Berg B-2220, Белгия |
3396.2 |
679.24 |
4075.44 |
4% |
10 |
3406.2 |
681.24 |
4087.44 |
16% |
25 |
3431.2 |
686.24 |
4117.44 |
|
НСР-7751/18.12.2015. (допуска предварително изпълнение); HCP-10161/31.08.2016 |
02.10.2016 |
02.10.2016 |
Неактивен |
4157 |
| Pembrolizumab |
EU/1/15/1024/001 |
Keytruda, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
Schering-Plough Labo NV, Industriepark 30 Heist-op-den-Berg B-2220, Белгия |
3396.2 |
679.24 |
4075.44 |
4% |
10 |
3406.2 |
681.24 |
4087.44 |
16% |
25 |
3431.2 |
686.24 |
4117.44 |
|
НСР-7751/18.12.2015. (допуска предварително изпълнение); HCP-10161/31.08.2016 |
02.10.2016 |
02.10.2016 |
Неактивен |
4157 |
| Pembrolizumab |
EU/1/15/1024/001 |
Keytruda, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Merck Sharp & Dohme Ltd., Обединено Кралство |
Schering-Plough Labo NV, Industriepark 30 Heist-op-den-Berg B-2220, Белгия |
3491.16 |
698.23 |
4189.39 |
4% |
10 |
3501.16 |
700.23 |
4201.39 |
16% |
25 |
3526.16 |
705.23 |
4231.39 |
|
НСР-7751/18.12.2015. (допуска предварително изпълнение) |
18.12.2015 |
18.12.2015 |
Неактивен |
4157 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05329/004 |
KIOVIG, Solution for infusion, 10 g/100 ml(100 mg/ml), mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
754.21 |
150.84 |
905.05 |
6% |
15 |
769.21 |
153.84 |
923.05 |
18% |
30 |
799.21 |
159.84 |
959.05 |
цената е заличена с решение КЦРР-770/07.06.2012 |
КЦРР-430/19.04.2012 |
27.06.2012 |
27.06.2012 |
Заличен |
1170 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05329/004 |
KIOVIG, Solution for infusion, 20 g/ 200 ml (100 mg/ ml), mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
1570.16 |
314.03 |
1884.19 |
6% |
15 |
1585.16 |
317.03 |
1902.19 |
18% |
30 |
1615.16 |
323.03 |
1938.19 |
цената е заличена с решение КЦРР-770/07.06.2012 |
КЦРР-430/19.04.2012 |
27.06.2012 |
27.06.2012 |
Заличен |
1171 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05329/002 |
KIOVIG, Solution for infusion, 2.5 g/25 ml (100 mg/ml), mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
174.87 |
34.97 |
209.84 |
6% |
10.49 |
185.36 |
37.07 |
222.43 |
18% |
30 |
215.36 |
43.07 |
258.43 |
цената е заличена с решение КЦРР-770/07.06.2012 |
КЦРР-430/19.04.2012 |
27.06.2012 |
27.06.2012 |
Заличен |
1168 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05329/003 |
KIOVIG, Solution for infusion, 5 g/ 50 ml (100 mg/ ml), mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
376.63 |
75.33 |
451.96 |
6% |
15 |
391.63 |
78.33 |
469.96 |
18% |
30 |
421.63 |
84.33 |
505.96 |
цената е заличена с решение КЦРР-770/07.06.2012 |
КЦРР-430/19.04.2012 |
27.06.2012 |
27.06.2012 |
Заличен |
1169 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05329/001 |
KIOVIG, Solution for infusion, 1 g/ 10 ml, mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
69.41 |
13.88 |
83.29 |
6% |
4.16 |
73.57 |
14.71 |
88.28 |
18% |
12.49 |
86.06 |
17.21 |
103.27 |
цената е заличена с решение КЦРР-770/07.06.2012 |
КЦРР-430/19.04.2012 |
27.06.2012 |
27.06.2012 |
Заличен |
1167 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05/329/005 |
KIOVIG, Solution for infusion, 20 g/ 200 ml (100 mg/ ml), mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
1599.87 |
319.97 |
1919.84 |
6% |
15 |
1614.87 |
322.97 |
1937.84 |
18% |
30 |
1644.87 |
328.97 |
1973.84 |
|
КЦ-1336/28.01.2010 |
17.02.2010 |
17.02.2010 |
Неактивен |
1171 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05/329/003 |
KIOVIG, Solution for infusion, 5 g/ 50 ml (100 mg/ ml), mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
399.97 |
79.99 |
479.96 |
6% |
15 |
414.97 |
82.99 |
497.96 |
18% |
30 |
444.97 |
88.99 |
533.96 |
|
КЦ-1336/28.01.2010 |
17.02.2010 |
17.02.2010 |
Неактивен |
1169 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05/329/004 |
KIOVIG, Solution for infusion, 10 g/100 ml(100 mg/ml), mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
799.93 |
159.99 |
959.92 |
6% |
15 |
814.93 |
162.99 |
977.92 |
18% |
30 |
844.93 |
168.99 |
1013.92 |
|
КЦ-1336/28.01.2010 |
17.02.2010 |
17.02.2010 |
Неактивен |
1170 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05/329/001 |
KIOVIG, Solution for infusion, 1 g/ 10 ml, mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
79.99 |
16 |
95.99 |
6% |
4.8 |
84.79 |
16.96 |
101.75 |
18% |
14.4 |
99.19 |
19.84 |
119.03 |
|
КЦ-1336/28.01.2010 |
17.02.2010 |
17.02.2010 |
Неактивен |
1167 |
| Immunoglobuline, normal human for extravascular adm. |
EU/1/05/329/002 |
KIOVIG, Solution for infusion, 2.5 g/25 ml (100 mg/ml), mg, Pack: 1 |
Baxter AG, Австрия |
BAXTER SA - Belgium |
199.98 |
40 |
239.98 |
6% |
12 |
211.98 |
42.4 |
254.38 |
18% |
30 |
241.98 |
48.4 |
290.38 |
|
КЦ-1336/28.01.2010 |
17.02.2010 |
17.02.2010 |
Неактивен |
1168 |
| Ribociclib |
EU/1/17/1221/003 |
Kisqali, Film coated tablet, 200, mg, Pack: 42 |
Novartis Europharm Limited, Ирландия |
Novartis Pharma GmbH, Германия |
2981.55 |
596.31 |
3577.86 |
4% |
10 |
2991.55 |
598.31 |
3589.86 |
16% |
25 |
3016.55 |
603.31 |
3619.86 |
|
НСР-19895/27.09.2019 - Предварително изпълнение; НСР-21555/28.05.2020 |
12.06.2020 |
02.07.2020 |
Активен |
16092 |
| Ribociclib |
EU/1/17/1221/003 |
Kisqali, Film coated tablet, 200, mg, Pack: 42 |
Novartis Europharm Limited, Ирландия |
Novartis Pharma GmbH, Германия |
2981.55 |
596.31 |
3577.86 |
4% |
10 |
2991.55 |
598.31 |
3589.86 |
16% |
25 |
3016.55 |
603.31 |
3619.86 |
|
НСР-19895/27.09.2019 - Предварително изпълнение; НСР-21555/28.05.2020 |
12.06.2020 |
02.07.2020 |
Неактивен |
16092 |
| Ribociclib |
EU/1/17/1221/003 |
Kisqali, Film coated tablet, 200, mg, Pack: 42 |
Novartis Europharm Limited, Ирландия |
Novartis Pharma GmbH, Германия |
3138.46 |
627.69 |
3766.15 |
4% |
10 |
3148.46 |
629.69 |
3778.15 |
16% |
25 |
3173.46 |
634.69 |
3808.15 |
|
НСР-19895/27.09.2019 - Предварително изпълнение |
02.10.2019 |
02.10.2019 |
Неактивен |
16092 |
| Ribociclib |
EU/1/17/1221/001 |
Kisqali, Film coated tablet, 200, mg, Pack: 21 |
Novartis Europharm Limited, Ирландия |
Novartis Pharma GmbH, Германия |
1490.75 |
298.15 |
1788.9 |
4% |
10 |
1500.75 |
300.15 |
1800.9 |
16% |
25 |
1525.75 |
305.15 |
1830.9 |
|
НСР-19895/27.09.2019 - Предварително изпълнение; НСР-21554/28.05.2020 |
12.06.2020 |
02.07.2020 |
Активен |
16147 |
| Ribociclib |
EU/1/17/1221/001 |
Kisqali, Film coated tablet, 200, mg, Pack: 21 |
Novartis Europharm Limited, Ирландия |
Novartis Pharma GmbH, Германия |
1490.75 |
298.15 |
1788.9 |
4% |
10 |
1500.75 |
300.15 |
1800.9 |
16% |
25 |
1525.75 |
305.15 |
1830.9 |
|
НСР-19895/27.09.2019 - Предварително изпълнение; НСР-21554/28.05.2020 |
12.06.2020 |
02.07.2020 |
Неактивен |
16147 |
| Ribociclib |
EU/1/17/1221/001 |
Kisqali, Film coated tablet, 200, mg, Pack: 21 |
Novartis Europharm Limited, Ирландия |
Novartis Pharma GmbH, Германия |
1569.22 |
313.84 |
1883.06 |
4% |
10 |
1579.22 |
315.84 |
1895.06 |
16% |
25 |
1604.22 |
320.84 |
1925.06 |
|
НСР-19895/27.09.2019 - Предварително изпълнение |
02.10.2019 |
02.10.2019 |
Неактивен |
16147 |
| Abacavir, lamivudine |
EU/1/04/298/002 |
KIVEXA, Film coated tablet, 600 mg/300 mg, -, Pack: 30 |
Viiv Healthcare BV, Нидерландия |
Glaxo Wellcome Operations, United Kingdom |
428.95 |
85.79 |
514.74 |
4% |
10 |
438.95 |
87.79 |
526.74 |
16% |
25 |
463.95 |
92.79 |
556.74 |
Промяна на обстоятелства НСР-18219/22.03.2019 |
КЦРР-2465/27.02.2013; НСР-9122/27.04.2016; НСР-13548/18.08.2017; НСР-17255/14.11.2018 |
29.11.2018 |
02.05.2019 |
Активен |
1727 |
| Abacavir, lamivudine |
EU/1/04/298/002 |
KIVEXA, Film coated tablet, 600 mg/300 mg, -, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome Operations, United Kingdom |
428.95 |
85.79 |
514.74 |
4% |
10 |
438.95 |
87.79 |
526.74 |
16% |
25 |
463.95 |
92.79 |
556.74 |
|
КЦРР-2465/27.02.2013; НСР-9122/27.04.2016; НСР-13548/18.08.2017; НСР-17255/14.11.2018 |
29.11.2018 |
02.12.2018 |
Неактивен |
1727 |
| Abacavir, lamivudine |
EU/1/04/298/002 |
KIVEXA, Film coated tablet, 600 mg/300 mg, -, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome Operations, United Kingdom |
582.74 |
116.55 |
699.29 |
4% |
10 |
592.74 |
118.55 |
711.29 |
16% |
25 |
617.74 |
123.55 |
741.29 |
|
КЦРР-2465/27.02.2013; НСР-9122/27.04.2016; НСР-13548/18.08.2017 |
02.09.2017 |
02.10.2017 |
Неактивен |
1727 |
| Abacavir, lamivudine |
EU/1/04/298/002 |
KIVEXA, Film coated tablet, 600 mg/ 300 mg, -, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome Operations, United Kingdom |
589.37 |
117.87 |
707.24 |
4% |
10 |
599.37 |
119.87 |
719.24 |
16% |
25 |
624.37 |
124.87 |
749.24 |
|
КЦРР-2465/27.02.2013; НСР-9122/27.04.2016 |
02.06.2016 |
02.06.2016 |
Неактивен |
1727 |
| Abacavir, lamivudine |
EU/1/04/298/001-003 |
KIVEXA, Film coated tablet, 600 mg/ 300 mg, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome Operations, United Kingdom |
596.29 |
119.26 |
715.55 |
4% |
10 |
606.29 |
121.26 |
727.55 |
16% |
25 |
631.29 |
126.26 |
757.55 |
|
КЦРР-2465/27.02.2013 |
26.03.2013 |
26.03.2013 |
Неактивен |
1727 |
| Abacavir, lamivudine |
EU/1/04/298/001-003 |
KIVEXA, Film coated tablet, 600 mg/ 300 mg, mg, Pack: 30 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Glaxo Wellcome Operations, United Kingdom |
695.3 |
139.06 |
834.36 |
4% |
10 |
705.3 |
141.06 |
846.36 |
16% |
25 |
730.3 |
146.06 |
876.36 |
КЦ-1780/01.10.2010 за промяна на обстоятелства |
КЦ-262/27.10.2008 |
18.11.2008 |
18.11.2008 |
Неактивен |
1727 |